Skip to main content
. 2021 Jul 6;9(7):e002428. doi: 10.1136/jitc-2021-002428

Figure 3.

Figure 3

Treatment with ABL503 is well tolerated in cynomolgus monkeys. (A) Total 4 monkeys were injected with the indicated concentration of ABL503 four times at 7-day intervals. (B) The binding of ABL503 to targets, human (red) and monkey (blue) 4-1BB and PD-L1, was observed by single-antigen captured ELISA at indicated concentration. (C) Clinical parameters including AST and ALT were measured.